Chronic diseases include cardiac diseases, cancer, and diabetes, which are the leading causes of death and disability in many countries around the globe.
qPCR reagents are essential for the diagnosis of chronic diseases such as human immuno deficiency virus (HIV) and malaria. Both conditions have non-specific symptoms. The qPCR kits and mixers contain all the necessary PCR reagents for rapid, sensitive, and reproducible real-time detection of HIV and other diseases using highly specific primer pairs.
Access Full Report at @ https://www.databridgemarketresearch.com/reports/saudi-arabia-q-pcr-reagents-market
Data Bridge Market Research analyzes that the Saudi Arabia qPCR Reagents Market is expected to grow with a CAGR of 8.3% in the forecast period of 2023 to 2030 and is expected to reach USD 41,798.44 thousand by 2030. The reagent segment is projected to propel the market growth due to increase in early diagnosis rate.
Key Findings of the Study
Rise in Government Funding for Healthcare
The government, federations, and major market players are creating opportunities across developing countries. These initiatives by the players and government are helping the users to reach out to take advantage of the policies made for low-income and developing nations and making them aware of the diseases that are preventable if diagnosed earlier.
Investments in medical R&D may increase as healthcare spending rises. More studies are conducted in the areas of genetic research, illness monitoring, and diagnostics, which may increase demand for qPCR reagents. Healthcare facilities may increase the number and type of clinical tests they offer as they develop and enhance their services.
Thus, these steps by the federations, associations, and government are expected to create major opportunities for market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015–2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Type (Reagents and Consumables), Application (Clinical, Research, Food Product Safety Testing, Forensics, and Others), End User (Hospitals, Diagnostic Centres, Pharmaceutical and Biopharmaceutical Companies, Research and Academic Institute, Clinical Research Organization, Veterinary Labs, Forensic Laboratories, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others)
|
|
Country Covered
|
Saudi Arabia
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Swzerland), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Quantabio (U.S.), SINO BIOLOGICAL INC. (China), QIAGEN (U.S.), TAKARA BIO INC. (Japan), Enzo Life Sciences, Inc. (U.S.), Meridian Bioscience (U.S.), Cytek Biosciences (Tonbo Biosciences) (U.S.), Norgen Biotek Corp (Canada)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The Saudi Arabia qPCR reagents market is segmented into four notable segments based on type, application, end user, and distribution channel.
- On the basis of type, the market is segmented into reagents and consumables.
In 2023, reagents segment is anticipated to dominate the Saudi Arabia qPCR reagents market
In 2023, the reagents segment is expected to dominate the market with a 58.71% market share due to the increase in early diagnosis rate in Saudi Arabia.
- On the basis of application, the market is segmented into clinical, research, food product safety testing, Forensics, and others.
In 2023, clinical segment is expected to dominate the Saudi Arabia qPCR reagents market
In 2023, the clinical segment is expected to dominate the market with a 37.94% market share, due to the increased prevalence of chronic diseases.
- On the basis of end user, the market is segmented into hospitals, diagnostic centers, pharmaceutical and biopharmaceutical companies, research and academic institute, clinical research organization, veterinary labs, forensic laboratories, and others. In 2023, the hospitals segment is expected to dominate the market with a 27.73% market share and is expected to reach USD 12,434.99 thousand by 2030, growing with a CAGR of 9.3% in the forecast period of 2023 to 2030.
- On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2023, the direct tender segment is expected to dominate the market with a 66.60% market share and is expected to reach USD 28,111.35 thousand by 2030, growing with the CAGR of 8.4% in the forecast period of 2023 to 2030.
Major Players
Data Bridge Market Research analyses F. Hoffmann-La Roche Ltd (Swzerland), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Quantabio (U.S.) as the major market players in Saudi Arabia qPCR reagents market.
Market Developments
- In December 2021, Thermo Fisher Scientific Inc. announced that they have completed the acquisition of PPD, Inc. a leading Saudi Arabia provider of clinical research services to the biopharma and biotech industry. This acquisition has helped the company to increase its product portfolio and sales.
- In September 2021, Agilent Technologies, Inc. announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software and other products. This has increased the company’s product reach.
- In September 2021, Bio-Rad Laboratories, Inc. announced the partnership with Seegene, Inc., a Saudi Arabia leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products. This has increased the company’s product portfolio.
- In June 2021, Agilent Technologies, Inc. announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry which include instruments, columns, reagents, and supplies that seamlessly integrate with Agilent OpenLab and MassHunter software, and CrossLab services to maximize efficiency in biopharma labs. This has increased the company’s sales and product portfolio.
- In July 2020, Thermo Fisher Scientific Inc. announced the launch of the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes. This has increased the company’s revenue and product portfolio.
For more detailed information about the Saudi Arabia qPCR reagents market report, click here – https://www.databridgemarketresearch.com/reports/saudi-arabia-q-pcr-reagents-market
